A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...

The condition primarily affects people age 65 and older. There are two basic types of macular degeneration, dry and wet, medically referred to as non-exudative and exudative. About 85 to 90% of cases ...

Aflibercept biosimilar is under clinical development by Lupin and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet ...

CG-P5 peptide is under clinical development by Caregen and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / ...

The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu ...

Introduction/Background Anti-VEGF Dosing Regiments: Review of the Pertinent Studies Comparing the Anti-VEGF Dosing Strategies Conclusions References While ...